SEARCH
Search Details
Sakushima Ken
| Hokkaido University Hospital Institute of Health Science Innovation for Medical Care | Associate Professor |
Researcher basic information
■ Degree- Doctor of Philosophy, Hokkaido University, Dec. 2012
- Master of Public Health, Kyoto University, Mar. 2009
researchmap URLホームページURL■ Various IDs
J-Global ID■ Research Keywords and Fields
Research Field
- Life Science, Medical technology assessment, Regulatory Science
- Life Science, Neurology
- Informatics, Life, health and medical informatics
- Master's degree program, Graduate School of Medicine
- Doctoral (PhD) degree program, Graduate School of Medicine
Career
■ CareerCareer
- Apr. 2025 - Present
北海道大学病院, 医療・ヘルスサイエンス研究開発機構, 准教授・臨床研究開発センター長 - Jul. 2023 - Mar. 2025
北海道大学病院, 医療・ヘルスサイエンス研究開発機構, 特任准教授 - Jan. 2015 - Jun. 2023
独立行政法人医薬品医療機器総合機構, 審査専門員・主任専門員(臨床医学担当)など - Aug. 2016 - Aug. 2017
U.S. Food and Drug Administration(PMDAより派遣) - Jan. 2013 - Dec. 2014
北海道大学大学院医学研究科, レギュラトリーサイエンス部門評価科学分野, 特任助教(PMDAへ出向), 革新的医薬品・医療機器・再生医療製品実用化促進事業の人材交流にて(独)医薬品医療機器総合機構に出向 - Jan. 2009 - Dec. 2012
北海道大学病院, 神経内科, 医員(2012年7月-12月 北海道大学大学院医学研究科 RA) - Oct. 2008 - Dec. 2008
苫小牧市立病院, 神経内科, 医員 - Oct. 2006 - Mar. 2008
北海道大学病院, 神経内科, 医員 - Apr. 2006 - Sep. 2006
釧路労災病院, 神経内科, 医員 - Apr. 2005 - Mar. 2006
市立函館病院, 神経内科, 医員 - Apr. 2004 - Mar. 2005
滝川市立病院, 研修医 - May 2003 - Mar. 2004
北海道大学病院, 研修医
- Apr. 2009 - Dec. 2012, Hokkaido University, Graduate School of Medicine, 博士課程(医学博士), 早期修了
- Apr. 2008 - Mar. 2009, Kyoto University, Graduate School of Medicine, Public Health, 臨床研究者養成(MCR)コース
- Apr. 1997 - Mar. 2003, Sapporo Medical University, 医学部, 医学科
- Jul. 2025 - Present
北海道医学会, 評議員 - Apr. 2025 - Present
ARO協議会, 理事, Society - Mar. 2024 - Present
独立行政法人医薬品医療機器総合機構, 専門委員, Others - Nov. 2023 - Present
日本神経治療学会, 幹事, Society - Nov. 2020 - Present
日本神経治療学会, 評議員, Society - May 2025
日本臨床薬理学会 北海道・東北支部, 世話人 - May 2018 - Apr. 2024
The International Rare Diseases Research Consortium (IRDiRC), Therapies Scientific Committee (TSC), Society - Nov. 2018 - Jun. 2023
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), M11 EWG Clinical electronic Structured Harmonised Protocol (CeSHarP) Expert Working Group, Society - May 2019 - Sep. 2022
COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES (CIOMS), Working Group XI – Patient Involvement, Society
Research activity information
■ Awards- Mar. 2017, PhUSE, PhUSE Annual Computational Science Symposium 2017 Best Poster Presentation FDA Award
Electronic Study Data Submission for New Drug Application in Japan
Ken Sakushima;Hiroshi Sakaguchi;TJ Chen - Feb. 2013, 第32回高桑榮松奨学基金奨励賞
- 【神経疾患におけるドラッグロス問題を考える】[第2部]ALSにおけるドラッグ・ロスの現状、解決に向けて
佐久嶋 研
難病と在宅ケア, 32, 2, 8, 10, (株)日本プランニングセンター, May 2026
Japanese - 神経領域における臨床試験/臨床評価ガイドライン作成の取組み 神経領域における国内外の臨床試験/臨床評価ガイドライン
佐久嶋 研
神経治療学, 42, 3, 205, 208, (一社)日本神経治療学会, May 2025
Japanese - 日本のALS治験,治療開発のさらなる推進のために 筋萎縮性側索硬化症に関する治験推進のための医療DX・治験DX
佐久嶋 研
神経治療学, 42, 3, 369, 370, (一社)日本神経治療学会, May 2025
Japanese - 【みんなで学び考えるALSの治験】(第1部)ALSの治験を推進するための取組み
佐久嶋 研
難病と在宅ケア, 31, 1, 10, 13, (株)日本プランニングセンター, Apr. 2025
Japanese - IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases.
Rajesh Krishna; Anneliene H Jonker; Thomas Morel; Ken Sakushima; Anna M G Pasmooij; Daniel O'Connor
Nature reviews. Drug discovery, 24, 4, 233, 234, Apr. 2025, [International Magazine]
English - 【神経治療学の最前線 知っておきたい最近の開発動向,規制,研究基盤のトピック】神経疾患治療薬の世界的な開発動向と日本の創薬の現状
佐久嶋 研
神経治療学, 42, 1, 8, 12, (一社)日本神経治療学会, Jan. 2025
Japanese - 【ドラッグ・ラグ/ロス時代における神経・筋疾患に対するリハビリテーション治療】本邦におけるオーファンドラッグ開発の現状と課題
佐久嶋 研
The Japanese Journal of Rehabilitation Medicine, 61, 12, 1135, 1140, (公社)日本リハビリテーション医学会, Dec. 2024
Japanese - PMDAに飛び込んでみよう:PMDAとのさらなる連携に向けて PMDAでの経験とその後 アカデミアにおけるレギュラトリーサイエンスへ
佐久嶋 研
神経治療学, 41, 3, 418, 419, (一社)日本神経治療学会, May 2024
Japanese - The Movement Disorder Society Criteria: Its Clinical Usefulness in Multiple System Atrophy.
Monami Tarisawa; Masaaki Matsushima; Akihiko Kudo; Ken Sakushima; Yasuhiro Kanatani; Naoki Nishimoto; Jun Sawada; Takeshi Matsuoka; Shin Hisahara; Haruo Uesugi; Naoya Minami; Kazuya Sako; Asako Takei; Akiko Tamakoshi; Norihiro Sato; Hidenao Sasaki; Ichiro Yabe
Internal medicine (Tokyo, Japan), 63, 21, 2903, 2912, 18 Mar. 2024, [Domestic magazines]
English, Scientific journal, Objective In 2022, Wenning et al. proposed the Movement Disorder Society Criteria (MDS Criteria) for the Diagnosis of Multiple System Atrophy (MSA). These criteria were expected to provide useful alternatives to the second consensus statement. We examined trends in these diagnostic criteria. Methods We used patient data registered with the Hokkaido Rare Disease Consortium for Multiple System Atrophy, which has been recruiting patients with MSA through medical facilities in Hokkaido since November 2014. Patients were evaluated according to the MDS criteria based on neurological examinations and imaging findings at three separate times: the first evaluation, the time of enrollment (diagnosis), and the most recent evaluation (final evaluation). Results The MDS criteria were examined in 68 of 244 patients enrolled between November 2014 and July 2022. At the initial evaluation, the classifications were as follows: clinically established (n=27; 39.7%); clinically probable (n=13; 19.1%); possible prodromal (n=12; 17.6%); and negative (did not meet criteria (n=16; 23.5%). At the time of diagnosis, the classifications were as follows: clinically established (n=45; 66.2%); clinically probable (n=12; 17.6%); possible prodromal (n=4; 5.9%); and negative (n=7; 10.3%). At the final evaluation, the classifications were as follows: clinically established (n=52; 76.5%); clinically probable (n=9; 13.2%); possible prodromal (n=2; 2.9%); and negative (n=5; 7.4%). Conclusions We were able to clarify the changes in the criteria values and transition of patients due to the clarification of imaging and supportive findings in the MDS criteria. - Are There Shortages and Regional Disparities in Lecanemab Treatment Facilities? A Cross-Sectional Study.
Kazuki Ohashi; Ikuko Takahashi-Iwata; Zhao Jieyu; Ken Sakushima; Ichiro Yabe; Katsuhiko Ogasawara
Health services insights, 17, 11786329241299312, 11786329241299312, 2024, [International Magazine]
English, Scientific journal, INTRODUCTION: Alzheimer disease (AD) is the most common type of dementia, affecting 70% of patients with dementia. In Japan, over 5 million people aged 65 years and older had dementia in 2018, and this figure is expected to rise to 25% to 30% of this age group by 2045. In Japan, lecanemab, which was approved in 2023, is expected to be a new treatment for AD. However, lecanemab requires stringent management, including amyloid PET scans and MRI monitoring, necessitating specialized facilities, creating concerns regarding the lack of treatment facilities and poor treatment access. METHODS: This study assessed spatial accessibility to lecanemab in Hokkaido, Japan, using geographic information system data. Hospitals were categorized into 3 scenarios based on their capacity to meet the treatment criteria. Service area analysis in each scenario evaluated the population coverage within 30-, 60-, and 120-minute travel times. The inverted two-step floating catchment area method was used to calculate the potential high-demand areas index (PHDI) for each hospital. RESULTS: Population coverage ranged from 56% to 97%, depending on the scenario and travel time. Coverage for the most feasible scenario (Scenario 1) was 56%, 73.9%, and 88.3% within 30, 60, and 120 minutes, respectively. Northern and southern Hokkaido had the lowest coverage. PHDI analysis identified high-demand areas, with Sapporo facing potential overcapacity issues. CONCLUSION: Lecanemab highlights the need for strategic resource allocation to enhance accessibility and capacity. Establishing additional treatment centers, particularly in areas with poor accessibility and capacity, is crucial to maximize the benefits of treatment for dementia. - Smoking and younger age at onset in anti-acetylcholine receptor antibody-positive myasthenia gravis
Yusei Miyazaki; Ken Sakushima; Masaaki Niino; Eri Takahashi; Kei Oiwa; Ryoji Naganuma; Itaru Amino; Sachiko Akimoto; Naoya Minami; Ichiro Yabe; Seiji Kikuchi
Immunological Medicine, 03 Apr. 2023, [Peer-reviewed]
Scientific journal - Orphan drug designation and development in Japan: 25 years of experience and assessment.
Ken Sakushima; Hiroshi Takeda; Yoko Aoi
Nature reviews. Drug discovery, 20, 12, 893, 894, Dec. 2021, [International Magazine]
English - Association of Smoking and Generalized Manifestations of Myasthenia Gravis.
Yusei Miyazaki; Masaaki Niino; Ken Sakushima; Eri Takahashi; Ryoji Naganuma; Itaru Amino; Sachiko Akimoto; Naoya Minami; Ichiro Yabe; Seiji Kikuchi
Internal medicine (Tokyo, Japan), 06 Nov. 2021, [Domestic magazines]
English, Scientific journal, Objectives Smoking is a known risk factor for the development and progression of autoimmune diseases. Previous studies in ocular myasthenia gravis (MG) patients showed that smoking is associated with the severity of symptoms and progression to generalized MG. However, whether smoking affects MG symptoms in patients with a broader clinical spectrum of presentations is unknown. Therefore, in this study, the associations of smoking with the clinical characteristics of MG were analyzed in a cohort of patients including those with generalized, seronegative, and thymoma-associated MG. Methods The smoking history was investigated in a cross-sectional study of 187 patients with MG followed in a referral hospital for neurology. The association of smoking with MG-activities of daily living score at survey, the presence of generalized manifestations, and the age of onset was assessed using multiple regression models. Results Neither current nor prior smoking habit was associated with the MG-activities of daily living score at survey. However, smoking exposure after MG onset was significantly associated with the presence of generalized manifestations during the disease course (odds ratio, 3.57; 95% confidence interval, 1.04, 12.3). The smoking history before or at onset of MG was not associated with the age of onset. Conclusion Smoking exposure after the onset is associated with generalized manifestations of MG in our cohort of patients with a broad clinical spectrum of presentations. - Multiple system atrophy in Hokkaido, Japan: a prospective registry study of natural history and symptom assessment scales followed for 5 years.
Masaaki Matsushima; Ichiro Yabe; Ken Sakushima; Yasuhiro Kanatani; Naoki Nishimoto; Takeshi Matsuoka; Jun Sawada; Haruo Uesugi; Kazuya Sako; Asako Takei; Akiko Tamakoshi; Shun Shimohama; Norihiro Sato; Seiji Kikuchi; Hidenao Sasaki
BMJ open, 11, 2, e045100, 08 Feb. 2021, [International Magazine]
English, Scientific journal, OBJECTIVES: Multiple system atrophy (MSA) is a refractory neurodegenerative disease, but novel treatments are anticipated. An accurate natural history of MSA is important for clinical trials, but is insufficient. This regional registry was launched to complement clinical information on MSA. SETTING: Patient recruitment started in November 2014 and is ongoing at the time of submission. The number of participating facilities was 66. Postal surveys were sent to medical facilities and patients with MSA in Hokkaido, Japan. PARTICIPANTS: After obtaining written consent from 196 participants, 184 overview surveys and 115 detailed surveys were conducted. PRIMARY AND SECONDARY OUTCOME MEASURES: An overview survey evaluated conformity to diagnostic criteria and a detailed survey implemented an annual assessment based on the Unified Multiple System Atrophy Rating Scale (UMSARS). RESULTS: At the time of registration, 58.2% of patients were diagnosed with cerebellar symptoms predominant type MSA (MSA-C) and 29.9% were diagnosed with parkinsonism predominant type MSA (MSA-P). UMSARS Part Ⅳ score of 4 or 5 accounted for 53.8% of participants. The higher the UMSARS Part Ⅳ score, the higher the proportion of MSA-P. At baseline, levodopa was used by 69 patients (37.5%) and the average levodopa dose was 406.7 mg/day. The frequency of levodopa use increased over time. Eleven cases changed from MSA-C to MSA-P during the study, but the opposite was not observed. Information about survival and causes of death was collected on 54 cases. Half of deaths were respiratory-related. Sudden death was recorded even in the group with UMSARS Part Ⅳ score of 1. CONCLUSIONS: This study is the first large-scale prospective MSA cohort study in Asia. MSA-C was dominant, but the use of antiparkinsonian drugs increased over the study period. Changes from MSA-C to MSA-P occurred, but not vice versa. - 有効性に関するトピックの動向 ICH M11 電子的に構造化された臨床試験プロトコル調和テンプレート(CeSHarP:Clinical electronic Structured Harmonised Protocol)
佐久嶋 研; 三上 素樹
医薬品医療機器レギュラトリーサイエンス, 51, 10, 542, 545, (一財)医薬品医療機器レギュラトリーサイエンス財団, Oct. 2020
Japanese - Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook.
Anneliene Hechtelt Jonker; Virginie Hivert; Michela Gabaldo; Liliana Batista; Daniel O'Connor; Annemieke Aartsma-Rus; Simon Day; Ken Sakushima; Diego Ardigo
Nature reviews. Drug discovery, 19, 8, 495, 496, Aug. 2020, [International Magazine]
English - 神経変性疾患に対する医師主導治験とエビデンス構築 神経変性疾患の臨床試験のポイント
佐久嶋 研
神経治療学, 37, 3, 363, 367, (一社)日本神経治療学会, May 2020
Japanese - Analysis of the Implementation of Blood Tests Specified in the Package Insert After Prescription of Thiamazole.
Yasuyuki Nasuhara; Ken Sakushima; Hiromitsu Oki; Takehiro Yamada; Ken Iseki; Reona Umeki; Akira Endoh
Journal of patient safety, 16, 1, 24, 29, Mar. 2020, [International Magazine]
English, Scientific journal, OBJECTIVES: The antithyroid drug thiamazole has long been known to cause the serious adverse effect of agranulocytosis, and performing regular blood tests is listed among the warnings on the package insert. We conducted a retrospective survey of how often doctors conducted blood tests in accordance with the package insert when thiamazole was prescribed at our hospital. METHODS: The subjects were patients to whom thiamazole was newly prescribed at our hospital between April 2004 and March 2012. During the target period, thiamazole was newly prescribed to 438 patients. RESULTS: We found that blood tests after prescription of thiamazole as listed in the warning section on the package insert are not performed sufficiently. The rate at which white blood cell counts were obtained decreased over time. The rate at which differential leukocyte counts were obtained was approximately 80% of white blood cell counts at all observational time points. In contrast, the percentage of subjects whose white blood cell counts were measured increased according to a time-trend analysis. CONCLUSIONS: This study revealed that blood tests after prescription of thiamazole as listed in the warning section on the package insert are not performed sufficiently at our hospital. The rate at which differential leukocyte counts were obtained was approximately 80% of white blood cell counts at all observational periods. Physician education should be more rigorously performed than presently done, and automatic generation of warnings that urge blood tests and patient education regarding the importance of blood tests is also important. - 医薬品医療機器総合機構における医師(臨床医学担当)の役割
佐久嶋 研
臨床麻酔, 43, 9, 1257, 1263, 真興交易(株)医書出版部, Sep. 2019
Japanese - Accelerating Cell Therapy for Stroke in Japan: Regulatory Framework and Guidelines on Development of Cell-Based Products.
Kiyohiro Houkin; Hideo Shichinohe; Koji Abe; Teruyo Arato; Mari Dezawa; Osamu Honmou; Nobutaka Horie; Yasuo Katayama; Kohsuke Kudo; Satoshi Kuroda; Tomohiro Matsuyama; Ichiro Miyai; Izumi Nagata; Kuniyasu Niizuma; Ken Sakushima; Masanori Sasaki; Norihiro Sato; Kenji Sawanobori; Satoshi Suda; Akihiko Taguchi; Teiji Tominaga; Haruko Yamamoto; Toru Yamashita; Toshiki Yoshimine
Stroke, 49, 4, e145-e152, Apr. 2018, [International Magazine]
English, Scientific journal - Adequacy of initial evaluation of fever in long-term care facilities.
Kosuke Yamada; Takafumi Nakagawa; Hidenori Hatto; Junichiro Miyachi; Masato Narushima; Ken Sakushima; Shingo Fukuma; Yukari Yamada; Shunichi Fukuhara
Geriatrics & gerontology international, 17, 9, 1294, 1299, Sep. 2017, [Domestic magazines]
English, Scientific journal, AIM: Febrile residents in long-term care facilities (LTCF) might be inadequately evaluated by caregivers. The present study aimed to examine the factors associated with inadequacy of initial fever evaluations by caregivers at night in LTCF. METHODS: We carried out a cross-sectional study among a convenience sample of caregivers employed at 11 LTCF in Japan using a vignette-based questionnaire. The respondents were randomly assigned to one of two scenarios describing a mild or severe febrile episode in an LTCF resident at night. The respondents' thinking patterns were classified based on influential factors in their fever evaluation. Associations between adequacy of evaluation and respondents' characteristics were evaluated using generalized linear mixed models. RESULTS: A total of 34% of fever evaluations among caregivers were considered to be inadequate regarding the necessity for examination by a physician, due in most cases to underestimating the severity of the fever. Respondents' thinking patterns in fever evaluation were significantly associated with the adequacy of the evaluation. Caregivers who placed particular importance on the preferences of residents and families versus other factors including the resident's febrile condition, were more likely to make an inadequate evaluation than those who did not. CONCLUSIONS: Our findings here suggest that eagerness to comply with residents' preference in fever evaluation could prompt caregivers not to call for an appropriate diagnostic procedure. Geriatr Gerontol Int 2017; 17: 1294-1299. - Effects of age and glucose levels on lactate levels in cerebrospinal fluid examination of neurodegenerative diseases.
Fumihito Nakano; Ken Sakushima; Reona Umeki; Ichiro Yabe; Akira Endoh; Hidenao Sasaki
Journal of the neurological sciences, 378, 45, 48, 15 Jul. 2017, [International Magazine]
English, Scientific journal, Despite recent studies examining the association between neurodegenerative diseases and mitochondrial dysfunction, there are not sufficient data on factors that influence cerebrospinal fluid (CSF) lactate levels. Thus, we investigated factors that affect CSF lactate levels in neurodegenerative diseases. We extracted laboratory findings, including CSF lactate, glucose, and protein levels, and demographic and background information, including age and gender, from the electronic medical records of patients with neurodegenerative diseases in order to explore factors that have an impact CSF lactate levels. These patients had been admitted to our department and underwent a CSF examination between April 2007 and March 2015. Data from 83 patients (average age 64.5years; 45 males and 38 females) were analyzed. The patients' diagnoses included amyotrophic lateral sclerosis, multiple system atrophy, spinocerebellar degeneration, corticobasal syndrome, Parkinson's disease, and Huntington's disease. CSF lactate levels were higher in patients with a neurodegenerative disease who were aged 65years and older relative to those who were aged under 65years (p<0.05), and CSF lactate and glucose levels showed a moderate positive correlation (r=0.487). Age and CSF glucose levels influenced CSF lactate levels even after adjusting for gender, age, CSF protein levels, and CSF glucose levels. When investigating CSF lactate levels in neurodegenerative diseases, it is necessary to consider patients' age and CSF glucose levels. - アカデミアにおける再生医療製品の開発プロジェクトの中間レビューにより抽出された課題 北海道大学における経験から
沢登 健治; 佐久嶋 研; 荒戸 照世; 七戸 秀夫; 佐藤 典宏; 寳金 清博
レギュラトリーサイエンス学会誌, 7, 2, 91, 97, (一社)レギュラトリーサイエンス学会, May 2017
Japanese - 【中枢神経疾患における細胞治療】細胞治療のレギュラトリーサイエンス 細胞治療・再生医療に関する法律・制度・ガイダンス
佐久嶋 研; 猿田 克年
医学のあゆみ, 260, 7, 594, 599, 医歯薬出版(株), Feb. 2017
Japanese - 【筋ジストロフィー・筋疾患-最近の進歩】筋ジストロフィーの診療・マネジメント・基盤 PMDAとレギュラトリーサイエンス、希少疾病用医薬品 医療者・研究者のためのレギュラトリーサイエンスに関する基礎知識
佐久嶋 研; 猿田 克年
医学のあゆみ, 259, 1, 125, 130, 医歯薬出版(株), Oct. 2016
Japanese - Influence of family dynamics on burden among family caregivers in aging Japan.
Tesshu Kusaba; Kotaro Sato; Shingo Fukuma; Yukari Yamada; Yoshinori Matsui; Satoshi Matsuda; Takashi Ando; Ken Sakushima; Shunichi Fukuhara
Family practice, 33, 5, 466, 70, Oct. 2016, [International Magazine]
English, Scientific journal, BACKGROUND: Long-term care for the elderly is largely shouldered by their family, representing a serious burden in a hyper-aging society. However, although family dynamics are known to play an important role in such care, the influence of caring for the elderly on burden among caregiving family members is poorly understood. OBJECTIVE: To examine the influence of family dynamics on burden experienced by family caregivers. METHODS: We conducted a cross-sectional study at six primary care clinics, involving 199 caregivers of adult care receivers who need long-term care. Participants were divided into three groups based on tertile of Index of Family Dynamics for Long-term Care (IF-Long score), where higher scores imply poorer relationships between care receivers and caregiving family: best, <2; intermediate, 2 to <5; worst, ≥5. The mean differences in burden index of caregivers (BIC-11) between the three groups were estimated by linear regression model with adjustment for care receiver's activity of daily living and cognitive function. RESULTS: Mean age of caregivers was 63.2 years (with 40.7% aged ≥ 65 years). BIC-11 scores were higher in the worst IF-Long group (adjusted mean difference: 4.4, 95% confidence interval: 1.2 to 7.5) than in the best IF-Long group. We also detected a positive trend between IF-Long score and BIC-11 score (P-value for trend <0.01). CONCLUSION: Our findings indicate that family dynamics strongly influences burden experienced by caregiving family members, regardless of the care receiver's degree of cognitive impairment. These results underscore the importance of evaluating relationships between care receivers and their caregivers when discussing a care regimen for care receivers. - First Approval of Regenerative Medical Products under the PMD Act in Japan.
Akihide Konishi; Ken Sakushima; Soichiro Isobe; Daisaku Sato
Cell stem cell, 18, 4, 434, 5, 07 Apr. 2016, [International Magazine]
English - Comparison of Different Symptom Assessment Scales for Multiple System Atrophy.
Masaaki Matsushima; Ichiro Yabe; Koji Oba; Ken Sakushima; Yasunori Mito; Asako Takei; Hideki Houzen; Kazufumi Tsuzaka; Kazuto Yoshida; Yasunori Maruo; Hidenao Sasaki
Cerebellum (London, England), 15, 2, 190, 200, Apr. 2016, [International Magazine]
English, Scientific journal, To identify the most sensitive scale for use in clinical trials on multiple system atrophy (MSA), a short and sensitive scale is needed for MSA clinical trials. Potential candidates are the Unified MSA Rating Scale (UMSARS), Scale for the Assessment and Rating of Ataxia (SARA), Berg Balance Scale (BBS), MSA Health-Related Quality of Life scale (MSA-QoL), and Scales for Outcomes in Parkinson's Disease-Autonomic questionnaire (SCOPA-AUT). We enrolled patients with MSA from eight hospitals in Hokkaido, Japan. Board-certified neurologists assessed each patient at 6-month intervals and scored them on the UMSARS, SARA, BBS, MSA-QoL, and SCOPA-AUT. Score changes were evaluated using the standardized response mean (SRM). The correlation between disease duration and each score was examined. The first evaluation was conducted on 85 patients (60 patients with MSA cerebellar ataxia dominant subtype [MSA-C] and 25 patients with MSA Parkinsonism-dominant subtype [MSA-P]). Sixty-nine patients were examined after 6 months and 63 patients after 12 months. The UMSARS Part 4 had the largest SRM after 6 months and the SARA after 12 months. SRMs for MSA-P, the shorter duration group, and the early-onset group were larger than were those for MSA-C, the longer duration group, and the late-onset group. SRMs for items regarding skilled hand activities, walking, and standing were relatively large. Our study indicates that the UMSARS (parts 2 and 4), SARA, and BBS are sensitive scales for evaluating MSA progression over 12 months. Items with large SRMs effectively evaluated short-term changes. - Influence of urinary urgency and other urinary disturbances on falls in Parkinson's disease.
Ken Sakushima; Shin Yamazaki; Shingo Fukuma; Yasuaki Hayashino; Ichiro Yabe; Shunichi Fukuhara; Hidenao Sasaki
Journal of the neurological sciences, 360, 153, 7, 15 Jan. 2016, [International Magazine]
English, Scientific journal, INTRODUCTION: Falling is one of the most common and serious public health problems. It can cause injuries such as sprains and fractures, and hospitalization may be required for serious injuries. Patients with Parkinson's disease have a higher risk of falls, and urinary incontinence is a known risk factor for falls in the elderly. However, whether other urinary disturbances contribute to the risk of falling remains unclear. The purpose of this study was to identify the association between falls and urinary disturbances in Parkinson's disease. METHODS: A prospective cohort study was conducted at a single institution with a 6-month observation period. Subjects were ambulatory patients with Parkinson's disease. Assessments included patient demographics, disease severity measured by the Hoehn and Yahr scale, and urinary disturbances measured using the overactive bladder symptom score (OABSS). Falls were reported using a self-documented fall record. RESULTS: A total of 97 patients were included. Forty-four subjects experienced one or more falls during the observation period. The frequency of urination was not related to falling; however, mild urinary urgency, but not severe urinary urgency, increased the risk of falls by an odds ratio of 5.14 (95% confidence interval: 1.51-17.48). Mild urinary urgency was also associated with the time to the first fall and the frequency of falls. One third of falls occurred in the living room, and 13.8% of falls occurred on the way to/from the toilet. CONCLUSION: Falls in patients with Parkinson's disease might be associated with urinary urgency, but not with the frequency of urination. - Epidemiology of Multiple System Atrophy in Hokkaido, the Northernmost Island of Japan.
Ken Sakushima; Naoki Nishimoto; Masanori Nojima; Masaaki Matsushima; Ichiro Yabe; Norihiro Sato; Mitsuru Mori; Hidenao Sasaki
Cerebellum (London, England), 14, 6, 682, 7, Dec. 2015, [International Magazine]
English, Scientific journal, Multiple system atrophy (MSA) is an intractable neurodegenerative disorder that is characterized by various combinations of autonomic failure, cerebellar ataxia, and parkinsonism. We conducted an epidemiological study of MSA using the combined data of a national registry system and a postal survey in Hokkaido, Japan. A postal survey was conducted in 2013 based on national registry data from 2006 to 2011. This survey contained the current status of each patient with MSA that had been collected from attending physicians and recorded into a national registry. Survey items included date, outcomes, primary symptoms, and activities of daily living at the last medical examination. Confirmation data of the diagnosis by a board-certified neurologist was also collected. Based on the national registry data, 1,092 patients with MSA were selected as our target population. The response rate of the postal survey was 81% (885/1,092). After excluding inappropriate responses, 839 patients with MSA were analyzed. Forty-nine percent of the patients were male, and the mean onset age was 62.1 ± 10.4 years. A Kaplan-Meier survival curve revealed that patients with onset symptoms of cerebellar ataxia had a better prognosis than those with onset of parkinsonism or autonomic failure (p < 0.01). Additionally, we found that a higher onset age was associated with poor prognosis. We found that patients with cerebellar ataxia at onset had a better survival prognosis than those with parkinsonism or autonomic failure at onset and that patients with an older age at onset had a worse survival prognosis. - 改正薬事法下における再生医療等製品の開発戦略とPMDAの果たすべき役割 再生医療等製品 臨床試験の計画・実施におけるポイント(ヒト細胞加工製品を中心に)
佐久嶋 研
再生医療, 14, 4, 365, 369, (株)メディカルレビュー社, Nov. 2015
Japanese - Physicians' responses to computerized drug interaction alerts with password overrides.
Yasuyuki Nasuhara; Ken Sakushima; Akira Endoh; Reona Umeki; Hiromitsu Oki; Takehiro Yamada; Ken Iseki; Makoto Ishikawa
BMC medical informatics and decision making, 15, 74, 74, 28 Aug. 2015, [International Magazine]
English, Scientific journal, BACKGROUND: Although evidence has suggested that computerized drug-drug interaction alert systems may reduce the occurrence of drug-drug interactions, the numerous reminders and alerts generated by such systems could represent an excessive burden for clinicians, resulting in a high override rate of not only unimportant, but also important alerts. METHODS: We analyzed physicians' responses to alerts of relative contraindications and contraindications for coadministration in a computerized drug-drug interaction alert system at Hokkaido University Hospital. In this system, the physician must enter a password to override an alert and continue an order. All of the drug-drug interaction alerts generated between December 2011 and November 2012 at Hokkaido University Hospital were included in this study. RESULTS: The system generated a total of 170 alerts of relative contraindications and contraindication for coadministration; 59 (34.7 %) of the corresponding orders were cancelled after the alert was accepted, and 111 (65.3 %) were overridden. The most frequent contraindication alert was for the combination of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors and fibrates. No incidents involving drug-drug interactions were reported among patients who were prescribed contraindicated drug pairs after an override. CONCLUSIONS: Although computerized drug-drug interaction alert systems that require password overrides appear useful for promoting medication safety, having to enter passwords to override alerts may represent an excessive burden for the prescribing physician. Therefore, both patient safety and physicians' workloads should be taken into consideration in future designs of computerized drug-drug interaction alert systems. - 【神経疾患治療の進歩2014年】腫瘍性および肉芽腫性疾患の治療の進歩
佐久嶋 研; 佐々木 秀直
神経治療学, 32, 4, 479, 482, (一社)日本神経治療学会, Jul. 2015
Japanese - 被験者組入れ不良により中止された介入研究の失敗要因分析 事例検討
佐久嶋 研; 堀江 奈穂; 天野 虎次; 茂木 祐子; 西村 千佳子; 重松 明男; 大庭 幸治; 伊藤 陽一; 佐藤 典宏
薬理と治療, 43, Suppl.1, s94, s98, ライフサイエンス出版(株), May 2015
Japanese - グローバルな視点で学ぶ創薬と治験推進のための課題 神経領域の治験推進に関連する最近のトピック PMDAの視点から
佐久嶋 研
神経治療学, 32, 3, 394, 397, (一社)日本神経治療学会, May 2015
Japanese - Mentoring the next generation of physician-scientists in Japan: a cross-sectional survey of mentees in six academic medical centers.
Ken Sakushima; Hiroki Mishina; Shunichi Fukuhara; Kenei Sada; Junji Koizumi; Takashi Sugioka; Naoto Kobayashi; Masaharu Nishimura; Junichiro Mori; Hirofumi Makino; Mitchell D Feldman
BMC medical education, 15, 54, 54, 19 Mar. 2015, [International Magazine]
English, Scientific journal, BACKGROUND: Physician-scientists play key roles in biomedical research across the globe, yet prior studies have found that it is increasingly difficult to recruit and retain physician-scientists in research careers. Access to quality research mentorship may help to ameliorate this problem in the U.S., but there is virtually no information on mentoring in academic medicine in Japan. We conducted a survey to determine the availability and quality of mentoring relationships for trainee physician-scientists in Japan. METHODS: We surveyed 1700 physician-scientists in post-graduate research training programs in 6 academic medical centers in Japan about mentorship characteristics, mentee perceptions of the mentoring relationship, and attitudes about career development. RESULTS: A total of 683 potential physician-scientist mentees completed the survey. Most reported that they had a departmental mentor (91%) with whom they met at least once a month; 48% reported that they were very satisfied with the mentoring available to them. Mentoring pairs were usually initiated by the mentor (85% of the time); respondents identified translational research skills (55%) and grant writing (50%) as unmet needs. Mentoring concerning long-term career planning was significantly associated with the intention to pursue research careers, however this was also identified by some mentees as an unmet need (35% desired assistance; 15% reported receiving it). CONCLUSIONS: More emphasis and formal training in career mentorship may help to support Japanese physician-scientist mentees to develop a sense of self-efficacy to pursue and stay in research careers. - Exploration of failure causes of an incomplete clinical trial in enrollment: A case study
Sakushima K; Horie N; Amano T; Mogi Y; Nishimura C; Shigematsu A; Oba K; Ito Y.M; Sato N
Japanese Pharmacology and Therapeutics, 43, s94, s98, 2015, [Peer-reviewed] - Time trend of injection drug errors before and after implementation of bar-code verification system.
Ken Sakushima; Reona Umeki; Akira Endoh; Yoichi M Ito; Yasuyuki Nasuhara
Technology and health care : official journal of the European Society for Engineering and Medicine, 23, 3, 267, 74, 2015, [International Magazine]
English, Scientific journal, BACKGROUND: Bar-code technology, used for verification of patients and their medication, could prevent medication errors in clinical practice. OBJECTIVE: Retrospective analysis of electronically stored medical error reports was conducted in a university hospital. METHODS: The number of reported medication errors of injected drugs, including wrong drug administration and administration to the wrong patient, was compared before and after implementation of the bar-code verification system for inpatient care. RESULTS: A total of 2867 error reports associated with injection drugs were extracted. Wrong patient errors decreased significantly after implementation of the bar-code verification system (17.4/year vs. 4.5/year, p< 0.05), although wrong drug errors did not decrease sufficiently (24.2/year vs. 20.3/year). The source of medication errors due to wrong drugs was drug preparation in hospital wards. CONCLUSION: Bar-code medication administration is effective for prevention of wrong patient errors. However, ordinary bar-code verification systems are limited in their ability to prevent incorrect drug preparation in hospital wards. - Developing a scale to measure family dynamics related to long-term care, and testing that scale in a multicenter cross-sectional study.
Tesshu Kusaba; Kotaro Sato; Yoshinori Matsui; Satoshi Matsuda; Takashi Ando; Ken Sakushima; Takafumi Wakita; Shingo Fukuma; Shunichi Fukuhara
BMC family practice, 15, 134, 134, 10 Jul. 2014, [International Magazine]
English, Scientific journal, BACKGROUND: As Japan's population ages, more frail elderly people are cared for by members of their family. The dynamics within such families are difficult to study, in part because they are difficult to quantify. We developed a scale for assessing family dynamics related to long-term care. Here we report on the development of that scale, and we present the results of reliability testing and validation testing. METHODS: Two primary-care specialists drafted questions about family dynamics, and discussed them with other primary-care physicians and clinical researchers. The final questionnaire asked about four problems or undesirable situations: disengagement (emotional distance), scapegoating (inappropriate blame), transfer of problems across generations (transfer of unnecessary burden from older to younger generations, trans-generationally displaced revenge), and undesirable behavior (co-dependence). Next, at six general-medicine clinics, doctors evaluated families that had a caregiver and a patient requiring long-term care. The results were analyzed by factor analysis. Cronbach's α was computed, and criterion-related validation tests were done with three types of criteria: relationship before caregiving, ability to do activities of daily living (ADL), and the duration of care. RESULTS: Results were obtained from 199 families. Among the caregivers, 79% were women and their mean age was 63 years. Among the patients, 71% were women and their mean age was 84 years. The results of factor analysis indicated that the scale was unidimensional. Cronbach's α was 0.73. Not having a good relationship before caregiving was associated with significantly worse family dynamics scores, as was greater dependence regarding ADL. CONCLUSIONS: We developed a scale that enables physicians to assess the dynamics of families with a patient and a family caregiver. The scale's scores are reliable and the results of validation testing were generally good. This scale holds promise as a tool both for research and for primary-care practice. - 【神経疾患治療の進歩2013年】腫瘍性および肉芽腫性疾患の治療の進歩
佐久嶋 研; 佐々木 秀直
神経治療学, 31, 4, 409, 411, (一社)日本神経治療学会, Jul. 2014
Japanese - 医学研究科大学院の若手研究者がメンターに望む指導の男女差
三品 浩基; 佐久嶋 研; 佐田 憲映; 小泉 順二; 杉岡 隆; 小林 直人; 西村 正治; 森 淳一郎; 槇野 博史; Feldman Mitchell D.; 福原 俊一
医学教育, 45, 1, 1, 7, (一社)日本医学教育学会, Feb. 2014
Japanese - 転倒・転落防止対策および対応に関する看護師の意識調査
南須原 康行; 佐久嶋 研; 奥原 芳子; 渋谷 かをり; 石川 誠; 宝金 清博
臨床看護, 39, 11, 1589, 1592, (株)へるす出版, Oct. 2013
Japanese, 転倒・転落対策の有効性と業務への影響および実際に経験した転倒・転落における対応内容を調査し、分析した。2012年6月に北海道大学病院の病院勤務をしている看護師を対象にアンケートを実施した。5項目の転倒対策、2011年10月から2012年3月迄に経験した転倒・転落インシデントの有無、経験がある場合に患者家族との対応について質問した。対象看護師は499名で、472名から回答を得ることができた。転倒・転落対策として、理解力が不十分な患者においては「有効」「非常に有効」を合わせると監視モニター、センサーマット、ベッド高・柵の調整が多かった。理解力がある患者に対しては、ベッド高・柵の調整とアセスメントシートが多かった。転倒・転落防止対策全般については、「有効であるがその対策を行う場合にはストレスを感じる」と54%が回答した。転倒・転落についての家族対応を行った看護師は116名であり、家族が医療者への不満を訴えたケースは2件のみであった。 - 多職種協同による病院情報システム・電子カルテデータを臨床研究に活用するプロセス
佐久嶋 研; 大庭 幸司; 西村 千佳子; 佐藤 典宏; 梅木 玲緒奈; 遠藤 晃
情報処理学会デジタルプラクティス, 4, 3, 244, 250, 情報処理学会, Jul. 2013, [Peer-reviewed], [Lead author]
Japanese, Scientific journal, 病院情報システムには各種オーダ情報や検査結果などが膨大なデータとして蓄積されている.このデータを臨床研究に活用するプロセスとして必要となる7 つのステップを提案する.7 つのステップは,1) リソースの確保,2) 研究テーマの決定,3) 対象者・対象データの選定,4) データ抽出と検証,5) データ管理,6) データ分析,7) 研究倫理に関する手続きからなる.これらのステップを推進するにあたっては,データが蓄積された現場を知っている医療者,実際にデータ保管を司る技術者,臨床研究の手法・医療統計に詳しい専門家が協同して実施することが,データの限界を把握した上で正しい結果を導くために重要であることを示す. - 【神経疾患治療の進歩2012年】腫瘍性および肉芽腫性疾患の治療の進歩
佐久嶋 研; 佐々木 秀直
神経治療学, 30, 4, 420, 422, (一社)日本神経治療学会, Jul. 2013
Japanese - 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease.
Kimihiro Ogisu; Kohsuke Kudo; Makoto Sasaki; Ken Sakushima; Ichiro Yabe; Hidenao Sasaki; Satoshi Terae; Mitsuhiro Nakanishi; Hiroki Shirato
Neuroradiology, 55, 6, 719, 24, Jun. 2013, [International Magazine]
English, Scientific journal, INTRODUCTION: Neuromelanin-sensitive MRI has been reported to be used in the diagnosis of Parkinson's disease (PD), which results from loss of dopamine-producing cells in the substantia nigra pars compacta (SNc). In this study, we aimed to apply a 3D turbo field echo (TFE) sequence for neuromelanin-sensitive MRI and to evaluate the diagnostic performance of semi-automated method for measurement of SNc volume in patients with PD. METHODS: We examined 18 PD patients and 27 healthy volunteers (control subjects). A 3D TFE technique with off-resonance magnetization transfer pulse was used for neuromelanin-sensitive MRI on a 3T scanner. The SNc volume was semi-automatically measured using a region-growing technique at various thresholds (ranging from 1.66 to 2.48), with the signals measured relative to that for the superior cerebellar peduncle. Receiver operating characteristic (ROC) analysis was performed at all thresholds. Intra-rater reproducibility was evaluated by intraclass correlation coefficient (ICC). RESULTS: The average SNc volume in the PD group was significantly smaller than that in the control group at all the thresholds (P < 0.01, student t test). At higher thresholds (>2.0), the area under the curve of ROC (Az) increased (0.88). In addition, we observed balanced sensitivity and specificity (0.83 and 0.85, respectively). At lower thresholds, sensitivity tended to increase but specificity reduced in comparison with that at higher thresholds. ICC was larger than 0.9 when the threshold was over 1.86. CONCLUSIONS: Our method can distinguish the PD group from the control group with high sensitivity and specificity, especially for early stage of PD. - Different surgical treatment techniques used by neurosurgeons and orthopedists for syringomyelia caused by Chiari I malformation in Japan.
Ken Sakushima; Kazutoshi Hida; Ichiro Yabe; Satoshi Tsuboi; Ritei Uehara; Hidenao Sasaki
Journal of neurosurgery. Spine, 18, 6, 588, 92, Jun. 2013, [International Magazine]
English, Scientific journal, OBJECT: Syringomyelia is a rare disease commonly caused by Chiari I malformation. Surgery by neurosurgeons and orthopedists is a critical treatment for symptomatic patients, and surgical techniques are associated with improved symptoms for these patients. The aim of this study was to determine the different surgical techniques used by neurosurgeons and orthopedists in Japan to treat syringomyelia caused by Chiari I malformation. METHODS: Patients who had undergone a surgical treatment were identified from a 2-stage postal survey conducted in late 2009. The authors compared the type of surgery performed and its association with cavity size reduction, on the basis of whether patients were receiving care in a neurosurgery or orthopedics department. RESULTS: A total of 232 patients with syringomyelia caused by Chiari I malformation were included in this study. Two-thirds of patients were treated in a neurosurgery department and the other third in an orthopedics department. Neurosurgeons preferred foramen magnum decompression (FMD) with dural patch grafting, and orthopedists preferred FMD with dural dissection. Foramen magnum decompression with dural patch grafting was associated with better outcomes than was dural dissection with regard to the following: motor impairment (66% vs. 39%, p < 0.05), sensory disturbance (60% vs. 43%, p = 0.051), pain (67% vs. 47%, p < 0.05), and cavity size (74% vs. 58%, p < 0.05). Improved motor function was associated more with cavity size reduction than with sensory disturbance and pain. CONCLUSIONS: Surgical procedures and outcomes differed, depending on whether the patient's care was managed in a neurosurgery or orthopedics department. Outcomes were better after FMD with dural patch grafting. - 7対1看護導入がインシデント報告件数に与えた影響について 新人看護職数の増加に着目して
南須原 康行; 佐久嶋 研; 奥原 芳子; 渋谷 かをり; 伊藤 陽一; 石川 誠; 宝金 清博
日本医療マネジメント学会雑誌, 14, 1, 25, 30, (NPO)日本医療マネジメント学会, May 2013
Japanese - 当院における成人用転倒・転落アセスメントシートの妥当性についての検討
南須原 康行; 佐久嶋 研; 伊藤 陽一; 奥原 芳子; 渋谷 かをり; 石川 誠; 宝金 清博
日本医療マネジメント学会雑誌, 14, 1, 31, 36, (NPO)日本医療マネジメント学会, May 2013
Japanese - Brain regions associated with cognitive impairment in patients with Parkinson disease: quantitative analysis of cerebral blood flow using 123I iodoamphetamine SPECT.
Naoya Hattori; Ichiro Yabe; Kenji Hirata; Tohru Shiga; Ken Sakushima; Sachiko Tsuji-Akimoto; Hidenao Sasaki; Nagara Tamaki
Clinical nuclear medicine, 38, 5, 315, 20, May 2013, [International Magazine]
English, Scientific journal, PURPOSE: Cognitive impairment is a representative neuropsychiatric presentation that accompanies Parkinson disease (PD). The purpose of this study was to localize the cerebral regions associated with cognitive impairment in patients with PD using quantitative SPECT. PATIENTS AND METHODS: Thirty-two patients with PD (mean [SD] age, 75 [8] years; 25 women; Hoehn-Yahr scores from 2 to 5) underwent quantitative brain SPECT using 123I iodoamphetamine. Parametric images of regional cerebral blood flow (rCBF) were spatially normalized to the standard brain atlas. First, voxel-by-voxel comparison between patients with PD with versus without cognitive impairment was performed to visualize overall trend of regional differences. Next, the individual quantitative rCBF values were extracted in representative cortical regions using a standard region-of-interest template to compare the quantitative rCBF values. RESULTS: Patients with cognitive impairment showed trends of lower rCBF in the left frontal and temporal cortices as well as in the bilateral medial frontal and anterior cingulate cortices in the voxel-by-voxel analyses. Region-of-interest-based analysis demonstrated significantly lower rCBF in the bilateral anterior cingulate cortices (right, 25.8 [5.5] vs 28.9 [5.7] mL per 100 g/min, P < 0.05; left, 25.8 [5.8] vs 29.1 [5.7] mL per 100 g/min, P < 0.05) associated with cognitive impairment. CONCLUSIONS: Patients with cognitive impairment showed lower rCBF in the left frontal and temporal cortices as well as in the bilateral medial frontal and anterior cingulate cortices. The results suggested dysexecutive function as an underlining mechanism of cognitive impairment in patients with PD. - Isolated granulomatous angiitis with eosinophilia in the central nervous system
Shirai, S; Yabe, I; Sakushima, K; Hiromi, K; Uwatoko, H; Hirotani, M; Kano, T; Kamoshima, Y; Tanaka, S; Sasaki, H
Neurology and Clinical Neuroscience, 1, 119, 121, Apr. 2013, [Peer-reviewed]
English - テキストマイニングを用いた学会誌論文タイトルの時系列分析 日本神経学会誌「臨床神経学」の分析
佐久嶋 研; 佐々木 秀直; 田代 邦雄
医療情報学, 32, 6, 315, 321, (一社)日本医療情報学会, Jan. 2013
Japanese - Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Hiroaki Yaguchi; Ken Sakushima; Ikuko Takahashi; Hiroaki Nishimura; Moemi Yashima-Yamada; Masakazu Nakamura; Kazufumi Tsuzaka; Yasunori Maruo; Toshiyuki Takahashi; Ichiro Yabe; Hidenao Sasaki
Internal medicine (Tokyo, Japan), 52, 9, 969, 72, 2013, [Domestic magazines]
English, Scientific journal, OBJECTIVE: Neuromyelitis optica (NMO) is an inflammatory disease that affects the optic nerve and spinal cord. Optic neuritis and longitudinally extensive myelitis associated with systemic autoimmune disease have been recently defined as NMO spectrum disorder (NMOSD). In this study, we report the efficacy of intravenous cyclophosphamide (IVCY) therapy for NMOSD. METHODS: Four patients diagnosed with NMOSD were enrolled in this study. The expanded disability status scale (EDSS) score was used to evaluate the degree of severity. All of the patients received intravenous methylprednisolone (IVMP; 1 g/day for three days), and two patients also received plasmapheresis (PP). All of the patients were administered IVCY treatment. RESULTS: Anti-AQP4 antibodies were present in the sera of all patients. All patients exhibited longitudinally extensive transverse myelitis (LETM). Only one patient who fulfilled the criteria for a diagnosis of NMO exhibited optic neuritis. Two patients developed relapse under treatment with low-dose prednisolone (PSL) before the administration of IVCY. The patients in this study exhibited a median improvement in the EDSS score following IVCY treatment from 8.0 to 5.75. Adverse effects were observed in only one patient. CONCLUSION: This study, despite its retrospective design, demonstrated the therapeutic efficacy of IVCY for NMOSD in both the acute and chronic phases of the disease and determined the IVCY dosage for Japanese women with NMOSD. Additionally, this study provided evidence that for NMOSD patients with severe disabilities, IVCY added to IVMP and PP may be a useful therapeutic modality. - 【内科診断の本道-病歴と身体診察情報からどこまでわかるか?】神経疾患 髄膜炎
佐久嶋 研; 佐々木 秀直
Medicina, 49, 9, 1598, 1601, (株)医学書院, Sep. 2012
Japanese - QI(Quality Indicator)による脳梗塞の診療の質の評価
佐久嶋 研; 中村 文明; 林野 泰明; 小崎 真規子; 上羽 哲也; 喜多田 祐子; 岩室 康司; 塩路 圭介; 福原 俊一
脳卒中, 34, 4, 235, 242, (一社)日本脳卒中学会, Jul. 2012
Japanese - 【神経疾患治療の進歩2011年】腫瘍性および肉芽腫性疾患の治療の進歩
佐久嶋 研; 佐々木 秀直
神経治療学, 29, 4, 405, 407, (一社)日本神経治療学会, Jul. 2012
Japanese - 長大な脊髄病変を呈し抗アクアポリン4抗体陰性を確認した単純ヘルペスウイルス脊髄炎が強く疑われた1例
白井 慎一; 佐久嶋 研; 水戸 泰紀; 矢部 一郎; 佐々木 秀直
神経治療学, 29, 4, 445, 449, (一社)日本神経治療学会, Jul. 2012
Japanese - Painless legs and moving toes from parasagittal meningioma.
Ichiro Yabe; Takahiro Kano; Ken Sakushima; Shunsuke Terasaka; Hidenao Sasaki
Movement disorders : official journal of the Movement Disorder Society, 27, 4, 586, 7, Apr. 2012, [International Magazine]
English - 【アカデミアから新規治療の実現へ-トランスレーショナルリサーチの現状】急がば回れ 臨床研究医の厚い層の育成は,将来の創薬研究を支える
福原 俊一; 佐久嶋 研; 西村 正治
BRAIN and NERVE: 神経研究の進歩, 64, 3, 225, 228, (株)医学書院, Mar. 2012
Japanese - Nationwide survey on the epidemiology of syringomyelia in Japan.
Ken Sakushima; Satoshi Tsuboi; Ichiro Yabe; Kazutoshi Hida; Satoshi Terae; Ritei Uehara; Imaharu Nakano; Hidenao Sasaki
Journal of the neurological sciences, 313, 1-2, 147, 52, 15 Feb. 2012, [International Magazine]
English, Scientific journal, BACKGROUND: Syringomyelia is a rare disease characterized by abnormal fluid-filled cavities within the spinal cord, and is associated with Chiari malformations, arachnoiditis, or spinal cord tumors. The widespread availability of magnetic resonance imaging (MRI) in Japan has allowed for easy identification of syrinxes. The aim of this study was to survey the clinicoepidemiological characteristics of syringomyelia in Japan. METHODS: A 2-stage postal survey was conducted in late 2009. The first survey aimed to estimate the number of patients with syringomyelia, and the second survey aimed to elucidate clinicoepidemiological characteristics. Diagnosis of syringomyelia was based on the findings of MRI or computed tomographic myelography. RESULTS: In the first survey, we received 2133 responses from 2937 randomly selected departments and collected data of 1215 syringomyelia patients (543 men and 672 women). The total response rate for the first survey was 73%. The estimated prevalence of ambulatory syringomyelia patients in Japan was 1.94 per 100000. In the second survey, the proportion of asymptomatic syringomyelia patients was 22.7%. Chiari type I malformations and idiopathic syringomyelia were the first and second most common etiologies. CONCLUSIONS: Our nationwide survey indicated that widespread MRI availability has contributed to the diagnosis of both asymptomatic and idiopathic cases. - Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients.
Ken Sakushima; Ichiro Yabe; Fumihito Nakano; Kazuto Yoshida; Yasutaka Tajima; Hideki Houzen; Yasunori Maruo; Hidenao Sasaki
Journal of neurology, 258, 12, 2163, 7, Dec. 2011, [International Magazine]
English, Scientific journal, The diagnosis of neurosarcoidosis is often difficult; the imaging signs of spinal cord sarcoidosis sometimes mimic those of cervical spondylotic myelopathy, which is common in elderly persons. We examined the characteristics of spinal cord sarcoidosis in Japanese patients with neurosarcoidosis. This case series identified patients with neurosarcoidosis at four general hospitals and one university hospital from April 1998 to September 2010. All diagnoses were based on the diagnostic criteria proposed by Zajicek et al. Seventeen patients (nine men and eight women) were involved: six patients with spinal cord lesions accompanied by cervical spondylosis, five with cerebral lesions, three with cranial nerve lesions, two with meningitis, and one with nerve root lesions. Patients with spinal cord sarcoidosis had a higher onset age, longer duration from onset to diagnosis, reduced leukocytosis in the cerebrospinal fluid (CSF), and lower angiotensin-converting enzyme (ACE) levels in the CSF. The results of this study indicate that diagnosis of spinal cord sarcoidosis requires careful evaluation. - 【内科 疾患インストラクションガイド 何をどう説明するか】神経・筋疾患 末梢神経障害
佐久嶋 研; 佐々木 秀直
Medicina, 48, 11, 385, 387, (株)医学書院, Nov. 2011
Japanese - Adult Leigh disease without failure to thrive.
Ken Sakushima; Sachiko Tsuji-Akimoto; Masaaki Niino; Shinji Saitoh; Ichiro Yabe; Hidenao Sasaki
The neurologist, 17, 4, 222, 7, Jul. 2011, [International Magazine]
English, Scientific journal, INTRODUCTION: Most Leigh disease (LD) patients die before reaching adulthood, but there are reports of "adult LD." The clinical features of adult LD were quite different from those in infant or childhood cases. Here, we describe a normally developed patient with adult LD, who presented with spastic paraplegia that was followed several years later by acute encephalopathy. We also conducted a systemic literature search on adult LD and integrated its various manifestations to arrive at a diagnostic procedure for adult LD. CASE REPORT: A 26-year-old woman presented with acute encephalopathy after spastic paraplegia. On her first admission, she exhibited bilateral basal ganglia lesion on magnetic resonance images and normal serum lactate levels. On second admission, she had acute encephalopathy with lactic acidosis and bilateral basal ganglia and brainstem lesions. A muscle biopsy revealed cytochrome c oxidase deficiency, and a diagnosis of adult LD was made. Despite treatment in the intensive care unit, she died 9 days after admission. CONCLUSIONS: A review of the literature describing adult LD revealed that developmental delay, COX deficiency, serum lactate elevation, and basal ganglia lesions occurred less frequently than they did in children with LD. Cranial nerve disturbance, pyramidal signs, and cerebellar dysfunction were the primary symptoms in adult LD. Thus, the many differences between childhood and adult LD may be helpful for diagnosing adult LD. - Idiopathic hypoglossal nerve laceration detected by high-resolution three-dimensional constructive interference in steady state magnetic resonance imaging.
Ken Sakushima; Satoshi Terae; Sachiko Tsuji-Akimoto; Masaaki Niino; Ichiro Yabe; Hidenao Sasaki
Journal of neuroimaging : official journal of the American Society of Neuroimaging, 21, 2, e177-9, Apr. 2011, [International Magazine]
English, Scientific journal, A 55-year-old man presented with acute onset dysarthria caused by left hypoglossal palsy. He had neither surgery nor injury prior to the onset of his symptoms. We detected no abnormalities with conventional magnetic resonance imaging (MRI) except for a slight gadolinium enhancement of the left hypoglossal nerve. Three-dimensional constructive interference in steady state MRI (CISS MRI) showed curling and thickening of the left hypoglossal nerve and fluid accumulation in the hypoglossal nerve canal. A systemic survey found no malignancies. After 8 months, sustained left hypoglossal palsy and no change in the MRI led to the diagnosis of idiopathic hypoglossal nerve laceration with evulsion. In such patients, the cause of the defect is not always apparent and 3-dimensional CISS MRI may resolve this issue. - Diagnostic accuracy of cerebrospinal fluid lactate for differentiating bacterial meningitis from aseptic meningitis: a meta-analysis.
Ken Sakushima; Yasuaki Hayashino; Takehiko Kawaguchi; Jeffrey L Jackson; Shunichi Fukuhara
The Journal of infection, 62, 4, 255, 62, Apr. 2011, [International Magazine]
English, Scientific journal, OBJECTIVES: Cerebrospinal fluid (CSF) lactate is produced by bacterial anaerobic metabolism and is not affected by blood lactate concentration, an advantage over CSF glucose in differentiating bacterial meningitis from aseptic meningitis. However, the previous investigations have shown mixed results of the sensitivity and specificity. Our study's purpose was to assess the utility of CSF lactate in differentiating bacterial meningitis from aseptic meningitis. METHODS: We searched MEDLINE and EMBASE for clinical studies that included CSF lactate measurement in bacterial meningitis and aseptic meningitis. Test characteristics were pooled using hierarchical summary ROC curve and random effects model. RESULTS: Thirty three studies were included. The pooled test characteristics of CSF lactate were sensitivity 0.93 (95% CI: 0.89-0.96), specificity 0.96 (95% CI: 0.93-0.98), likelihood ratio positive 22.9 (95% CI: 12.6-41.9), likelihood ratio negative 0.07 (95% CI: 0.05-0.12), and diagnostic odds ratio 313 (95% CI: 141-698). Pretreatment with antibiotics lowered the sensitivity 0.49 (95% CI: 0.23-0.75). CSF lactate of around 35 mg/dl (34-36 mg/dl) had higher sensitivity and specificity than those of around 27 mg/dl (26-28 mg/dl). CONCLUSIONS: CSF lactate's high negative likelihood ratio may make it useful for ruling out bacterial meningitis though pretreatment with antibiotics reduces clinical accuracy. CSF lactate of 35 mg/dl could be optimal cut-off value for distinguishing bacterial meningitis from aseptic meningitis. - 【認知症診療の実際 初診から介護まで】急速に進行する認知症をみたときに考えること
佐久嶋 研; 佐々木 秀直
診断と治療, 99, 3, 475, 479, (株)診断と治療社, Mar. 2011
Japanese - 妊婦健診では妊娠高血圧症候群を欠いた子癇の2例
佐久嶋 研; 水戸 泰紀; 矢口 裕章; 矢部 一郎; 佐々木 秀直
てんかんをめぐって, 29, 38, 43, 日本てんかん学会-北海道地方会, Mar. 2011
Japanese, 妊婦健診では妊娠高血圧症候群を欠いた子癇の2例を経験した。症例1は27歳女で、妊娠32週目に全身痙攣発作が出現し、呼名反応が無くなったため搬送された。搬入後にも痙攣発作あり、ジアゼパムを経静脈投与された。その後も痙攣発作が出現したため、ジアゼパム経静脈投与とフェノバルビタール筋肉内注射を追加した。脳MRI異常と髄液細胞数増多を認めた。全身麻酔下で帝王切開にて出産した。出産後は痙攣発作の再発無く、出産翌日には人工呼吸器を離脱した。最終的に妊娠子癇と診断した。症例2は20歳女で、経腟分娩を施行中、出産直前に間代性痙攣発作が出現した。発作は短時間で終息し、そのまま経腟分娩にて出産した。出産後会陰縫合中に2回目の痙攣発作が出現しジアゼパムを経静脈投与され、発作は消失した。髄液所見は正常であったが脳MRIにて異常を認め、分娩子癇と診断した。 - 画像的に多巣性の進展経過を示した大脳膠腫症の1例
佐久嶋 研; 山田 萌美; 久保田 佳奈子; 澤村 豊; 矢部 一郎; 佐々木 秀直
臨床神経学, 51, 2, 145, 148, (一社)日本神経学会, Feb. 2011
Japanese - FDG-PET SUV can distinguish between spinal sarcoidosis and myelopathy with canal stenosis.
Ken Sakushima; Ichiro Yabe; Tohru Shiga; Moemi Yashima-Yamada; Sachiko Tsuji-Akimoto; Satoshi Terae; Hidenao Sasaki
Journal of neurology, 258, 2, 227, 30, Feb. 2011, [International Magazine]
English, Scientific journal, Spinal cord sarcoidosis is a rare manifestation of sarcoidosis. Magnetic resonance imaging (MRI) of spinal cord sarcoidosis sometimes resembles that of the non-inflammatory spinal cord lesion. (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is an effective method to detect both systemic and central nervous system lesions in sarcoidosis. This study compared the standard uptake value (SUV) of FDG-PET between spinal cord sarcoidosis and non-inflammatory spinal cord lesions. We retrospectively reviewed the records of patients who underwent both spinal MRI and FDG-PET scans. We used SUV to evaluate the FDG-PET uptake of the lesion. The region of interest was the center of high-intensity areas on T2-weighted MR images. We included three patients with spinal cord sarcoidosis, five with myelomalacia caused by cervical spondylosis or ossification of the posterior longitudinal ligament, one with spinal cord edema associated with cervical spondylosis, and one with spinal cord edema associated with dural arteriovenous fistula. The spinal cord sarcoidosis group had a significantly higher SUV (mean 4.38, range 3.30-4.93) than patients with the other diseases (mean 1.87, range 1.42-2.74). The SUV of FDG-PET thus may be able to distinguish spinal cord sarcoidosis from other non-inflammatory lesions. FDG-PET can play an important role in the diagnosis of spinal cord sarcoidosis because the gadolinium enhancement in MRI is sometimes seen in spondylotic myelopathy or vascular malformation. FDG-PET is informative for the accurate diagnosis of spinal cord sarcoidosis and may enable clinicians to start treatment at an earlier stage. - Dissociation between the severity of cerebrospinal fluid hypovolemia and MRI findings.
Masaaki Matsushima; Ichiro Yabe; Hiroaki Nishimura; Ken Sakushima; Sachiko Akimoto; Masaaki Niino; Hidenao Sasaki
Journal of neurology, 257, 4, 665, 6, Apr. 2010, [International Magazine]
English - 頸椎症性脊髄症術後に診断された脊髄サルコイドーシスの1例
高橋 育子; 相馬 広幸; 佐久嶋 研; 秋本 幸子; 新野 正明; 矢部 一郎; 佐々木 秀直
神経治療学, 27, 2, 209, 213, (一社)日本神経治療学会, Mar. 2010
Japanese - Weakness and sensory disturbance of the left extremities.
Ken Sakushima; Masaaki Niino; Ichiro Yabe; Sachiko Akimoto-Tsuji; Hidenao Sasaki
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 16, 12, 1608, 1711, Dec. 2009, [International Magazine]
English, Scientific journal - 血液ガス分析装置による髄液乳酸および糖の迅速測定の信頼性
佐久嶋 研; 新野 正明; 秋本 幸子; 矢部 一郎; 佐々木 秀直
臨床神経学, 49, 5, 275, 277, (一社)日本神経学会, May 2009
Japanese - Downbeat positioning nystagmus is a common clinical feature despite variable phenotypes in an FHM1 family.
Ichiro Yabe; Mayumi Kitagawa; Yashio Suzuki; Keishi Fujiwara; Takahito Wada; Takashi Tsubuku; Norihito Takeichi; Ken Sakushima; Hiroyuki Soma; Sachiko Tsuji; Masaaki Niino; Shinji Saitoh; Hidenao Sasaki
Journal of neurology, 255, 10, 1541, 4, Oct. 2008, [International Magazine]
English, Scientific journal, Clinical examinations and mutational analyses were carried out in three patients of a Japanese familial hemiplegic migraine (FHM) pedigree. Each affected member demonstrated a broad clinical spectrum that included hemiplegic migraine with progressive cerebellar ataxia, migraine without aura, and episodic ataxia. Despite this variability, all members exhibited marked downbeat positioning nystagmus, and magnetic resonance images (MRI) all showed cerebellar atrophy predominantly of the cerebellar vermis. All affected members had a T666M missense mutation in the protein encoded by the CACNA1A gene (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit). Although clinical features associated with the T666M CACNA1A mutation are highly variable, downbeat positioning nystagmus may be an important clinical feature of this disease. - 健診にて偶然発見された頭痛をともなわない特発性頭蓋内圧亢進症の1例
佐久嶋 研; 辻 幸子; 新野 正明; 矢部 一郎; 佐々木 秀直
臨床神経学, 48, 6, 430, 432, (一社)日本神経学会, Jun. 2008
Japanese - 脳卒中片麻痺患者に対するcrook lyingの評価は有用か?
碓井 孝治; 川村 昌嗣; 森山 武; 齋藤 香織; 山下 康次; 片田 竜一; 飯星 智史; 橋本 祐治; 丹羽 潤; 佐久嶋 研; 横山 徳幸; 丸尾 泰則
函館医学誌, 30, 1, 64, 69, 市立函館病院, Sep. 2006
Japanese, 脳卒中に伴う片麻痺に対するリハビリにおいて、ベッドでの立て膝背臥位(crook lying)が歩行以前の端坐位獲得の可否或いは獲得までの期間に関与するのではないかとの仮説を立てた。この仮説を検証すべく、crook lyingと端坐位及び歩行との関係を他の機能障害に関する評価と共に後方視的に調査、検討した。68症例(男性46例、女性22例、平均67.2歳)を対象に検討を行った。疾患の内訳は、脳内出血18例、脳梗塞50例であった。その結果、crook lyingが可能であれば機能障害が軽度で端坐位が保持でき、歩行が自立する可能性が高く、自宅退院が可能であり、在院日数も短縮することが示された。crook lyingは早期離床を図り、より良いリハビリテーション医療を行う上で簡便な評価項目であり、有用な指標であると思われた。
- 多系統萎縮症における侵襲的治療介入の傾向とリスク因子の解析
市之川萌奈美; 松島理明; 佐久嶋研; 金谷泰宏; 西本尚樹; 澤田潤; 松岡健; 上杉春雄; 南尚哉; 佐光一也; 武井麻子; 久原真; 玉腰暁子; 佐藤典宏; 矢部一郎, 日本神経学会学術大会プログラム・抄録集, 66th, 2025 - 北海道における多系統萎縮症レジストリ研究:HoRC-MSA2014-2024
松島理明; 足澤萌奈美; 工藤彰彦; 佐久嶋研; 金谷泰宏; 西本尚樹; 澤田潤; 松岡健; 上杉春雄; 南尚哉; 佐光一也; 武井麻子; 久原真; 玉腰暁子; 佐藤典宏; 矢部一郎, 臨床神経学(Web), 64, 11, 2024 - 大学病院における多診療科連携型軽度認知障害センターの構築
岩田育子; 松島理明; 宇土仁木; 池辺洋平; 平田健司; 杉山拓; 森田真也; 渡邊裕; 向野雅彦; 中村昭伸; 佐久嶋研; 熊谷聡美; 藤村幹; 工藤與亮; 矢部一郎, Dementia Japan, 38, 4, 2024 - 北海道における多系統萎縮症レジストリ研究:HoRC-MSA2014・2023
松島理明; 足澤萌奈美; 工藤彰彦; 佐久嶋研; 金谷泰宏; 西本尚樹; 澤田潤; 松岡健; 上杉春雄; 南尚哉; 佐光一也; 武井麻子; 久原真; 玉腰暁子; 佐藤典宏; 佐々木秀直; 矢部一郎, 臨床神経学(Web), 63, 11, 2023 - 北海道における多系統萎縮症レジストリ研究:HoRC-MSA2014-2022
松島理明; 足澤萌奈美; 工藤彰彦; 佐久嶋研; 金谷素宏; 西本尚樹; 澤田潤; 松岡健; 久原真; 上杉春雄; 南尚哉; 佐光一也; 武井麻子; 玉腰暁子; 佐藤典宏; 佐々木秀直; 矢部一郎, 臨床神経学(Web), 62, 12, 2022 - 北海道における多系統萎縮症レジストリ研究:HoRC-MSA2014-2021
松島理明; 佐久嶋研; 金谷泰宏; 西本尚樹; 澤田潤; 松岡健; 久原真; 上杉春雄; 南尚哉; 佐光一也; 武井麻子; 玉腰暁子; 佐藤典宏; 佐々木秀直; 矢部一郎, 臨床神経学(Web), 62, 4, 2022 - 北海道における多系統萎縮症レジストリ研究:HoRC-MSA2014-2019
松島理明; 佐久嶋研; 矢部一郎; 金谷泰宏; 西本尚樹; 松岡健; 澤田潤; 上杉春雄; 上杉春雄; 佐光一也; 武井麻子; 玉腰暁子; 下濱俊; 佐藤典宏; 菊地誠志; 佐々木秀直; 佐々木秀直, 臨床神経学(Web), 60, 1, 2020 - 北海道における多系統萎縮症レジストリ研究:HoRC-MSA2014-2019
松島 理明; 佐久嶋 研; 矢部 一郎; 金谷 泰宏; 西本 尚樹; 松岡 健; 澤田 潤; 上杉 春雄; 佐光 一也; 武井 麻子; 玉腰 暁子; 下濱 俊; 佐藤 典宏; 菊池 誠志; 佐々木 秀直, 臨床神経学, 60, 1, 95, 95, Jan. 2020, [Peer-reviewed]
(一社)日本神経学会, Japanese - 北海道における多系統萎縮症レジストリ研究:HoRC-MSA2014-2018
松島理明; 佐久嶋研; 矢部一郎; 金谷泰宏; 大野浩太; 松岡健; 片山隆行; 上杉春雄; 佐光一也; 武井麻子; 下濱俊; 佐藤典宏; 菊地誠志; 佐々木秀直, 臨床神経学(Web), 59, 1, 2019 - 北海道における多系統萎縮症レジストリ研究:HoRC-MSA2014-2018
松島 理明; 佐久嶋 研; 矢部 一郎; 金谷 泰宏; 大野 浩太; 松岡 健; 片山 隆行; 上杉 春雄; 佐光 一也; 武井 麻子; 下濱 俊; 佐藤 典宏; 菊地 誠志; 佐々木 秀直; 北海道保健福祉部健康安全局地域保健課感染症; 特定疾患グループ, 臨床神経学, 59, 1, 49, 49, Jan. 2019
(一社)日本神経学会, Japanese - 北海道における多系統萎縮症レジストリ研究:HoRC-MSA2014-2017
松島 理明; 佐久嶋 研; 矢部 一郎; 金谷 泰宏; 伊藤 陽一; 松岡 健; 片山 隆行; 上杉 春雄; 佐光 一也; 武井 麻子; 下濱 俊; 佐藤 典宏; 菊地 誠志; 佐々木 秀直, 臨床神経学, 57, 12, 813, 813, Dec. 2017
(一社)日本神経学会, Japanese - 北海道における多系統萎縮症レジストリ研究:HoRC-MSA2014-2017
松島理明; 佐久嶋研; 矢部一郎; 金谷泰宏; 伊藤陽一; 松岡健; 片山隆行; 上杉春雄; 佐光一也; 武井麻子; 下濱俊; 佐藤典宏; 菊地誠志; 佐々木秀直, 臨床神経学(Web), 57, 12, 2017 - 北海道における多系統萎縮症レジストリ研究:HoRC‐MSA
松島理明; 佐久嶋研; 矢部一郎; 伊藤陽一; 片山隆行; 佐光一也; 森満; 下濱俊; 佐藤典宏; 菊地誠志; 佐々木秀直, 日本神経学会学術大会プログラム・抄録集, 57th, Suppl., 651, S484, Dec. 2016
(一社)日本神経学会, Japanese - 北海道における多系統萎縮症のレジストリ研究 HoRC-MSA 2015-2016
松島 理明; 佐久嶋 研; 矢部 一郎; 金谷 泰宏; 伊藤 陽一; 片山 隆行; 佐光 一也; 武井 麻子; 森 満; 下濱 俊; 佐藤 典宏; 菊地 誠志; 佐々木 秀直; 北海道保健福祉部健康安全局地域保健課感染症; 特定疾患グループ, 臨床神経学, 56, 11, 802, 802, Nov. 2016
(一社)日本神経学会, Japanese - The score changes of clinical symptom assessment scales for multiple system atrophy in 2-3 years
M. Matsushima; I. Yabe; I. Takahashi; K. Sakushima; F. Nakano; M. Hirotani; T. Kano; K. Horiuchi; H. Houzen; H. Sasaki, MOVEMENT DISORDERS, 31, S59, S59, Jun. 2016
English, Summary international conference - 北海道における多系統萎縮症のレジストリ研究:HoRC-MSA 2015-2016
松島理明; 佐久嶋研; 矢部一郎; 金谷泰宏; 伊藤陽一; 片山隆行; 佐光一也; 武井麻子; 森満; 下濱俊; 佐藤典宏; 菊地誠志; 佐々木秀直, 臨床神経学(Web), 56, 11, 2016 - 北海道における多系統萎縮症のレジストリ研究 HoRC-MSA step2
松島 理明; 佐久嶋 研; 矢部 一郎; 伊藤 陽一; 片山 隆行; 佐光 一也; 森 満; 下濱 俊; 佐藤 典宏; 菊地 誠志; 佐々木 秀直, 臨床神経学, 55, 12, 945, 945, Dec. 2015
(一社)日本神経学会, Japanese - 北海道における多系統萎縮症のレジストリ研究:HoRC‐MSA step 2
松島理明; 佐久嶋研; 矢部一郎; 伊藤陽一; 片山隆行; 佐光一也; 森満; 下濱俊; 佐藤典宏; 菊地誠志; 佐々木秀直, 臨床神経学(Web), 55, 12, 945(J‐STAGE), 945, Dec. 2015
(一社)日本神経学会, Japanese - 北海道における多系統萎縮症の疫学的実態 HoRC-MSAプロジェクト
佐久嶋 研; 西本 尚樹; 松島 理明; 野島 正寛; 矢部 一郎; 森 満; 佐藤 典宏; 佐々木 秀直, 臨床神経学, 55, 2, 131, 131, Feb. 2015
(一社)日本神経学会, Japanese - 北海道における多系統萎縮症の疫学的実態:HoRC-MSAプロジェクト
佐久嶋研; 西本尚樹; 松島理明; 野島正寛; 矢部一郎; 森満; 佐藤典宏; 佐々木秀直, 臨床神経学(Web), 55, 2, 2015 - 北海道における多系統萎縮症の疫学的実態:HoRC‐MSAプロジェクト
佐久嶋研; 西本尚樹; 野島正寛; 松島理明; 矢部一郎; 佐藤典宏; 森満; 佐々木秀直, 日本神経学会学術大会プログラム・抄録集, 55th, Suppl., 507, S38, Dec. 2014
(一社)日本神経学会, Japanese - Comparison of different symptom assessment scales for multiple system atrophy - Second report
M. Matsushima; I. Yabe; K. Oba; K. Sakushima; Y. Mito; A. Takei; H. Hozen; K. Tsuzaka; K. Yoshida; Y. Maruo; H. Sasaki, MOVEMENT DISORDERS, 29, S178, S178, May 2014
English, Summary international conference - 運動失調症の病態解明と治療法開発に関する研究 多系統萎縮症における症状評価スケールの比較(第2報)
佐々木秀直; 松島理明; 矢部一郎; 佐久嶋研; 大庭幸治; 水戸泰紀; 武井麻子; 保前英希; 津坂和文; 吉田一人; 丸尾泰則, 運動失調症の病態解明と治療法開発に関する研究 平成25年度 総括・分担研究報告書, 2014 - 北海道における多系統萎縮症の疫学的実態:HoRC‐MSAプロジェクト
佐久嶋研; 西本尚樹; 松島理明; 野島正寛; 矢部一郎; 森満; 佐藤典宏; 佐々木秀直, 臨床神経学, 54, 1, 89, 89, 01 Jan. 2014
(一社)日本神経学会, Japanese - 中枢神経原発血管炎5例の臨床像の検討
白井 慎一; 矢口 裕章; 上床 尚; 佐久嶋 研; 廣谷 真; 加納 崇裕; 矢部 一郎; 田中 伸哉; 佐々木 秀直, 臨床神経学, 53, 12, 1575, 1575, Dec. 2013
(一社)日本神経学会, Japanese - 神経Behcet病の臨床像および画像所見の検討
上床 尚; 佐久嶋 研; 加納 崇裕; 白井 慎一; 廣谷 真; 矢部 一郎; 佐々木 秀直, 臨床神経学, 53, 12, 1582, 1582, Dec. 2013
(一社)日本神経学会, Japanese - 中枢神経に限局したアレルギー性肉芽腫性血管炎の1例
白井 慎一; 上床 尚; 廣谷 真; 佐久嶋 研; 加納 崇裕; 鴨嶋 雄大; 矢部 一郎; 田中 伸哉; 佐々木 秀直, 臨床神経学, 53, 4, 320, 320, Apr. 2013
(一社)日本神経学会, Japanese - 運動失調症の病態解明と治療法開発に関する研究 多系統萎縮症における症状評価スケールの比較(中間報告)
佐々木秀直; 松島理明; 矢部一郎; 佐久嶋研; 大庭幸治; 水戸泰紀; 武井麻子; 保前英希; 津坂和文; 吉田一人; 丸尾泰則, 運動失調症の病態解明と治療法開発に関する研究 平成24年度 総括・分担研究報告書, 2013 - グループホーム介護職における発熱の重症度判断と受療行動に関する調査
成島仁人; 宮地純一郎; 八藤英典; 中川貴史; 山田康介; 福間真悟; 佐久嶋研; 佐瀬雄治; 草場鉄周; 福原俊一, 日本プライマリ・ケア連合学会学術大会抄録集, 4th, 2013 - 多系統萎縮症における血中matrix metalloproteinase 3(MMP3)とtissue inhibitor of metalloproteinase 1(TIMP1)の意義
佐々木 秀直; 矢部 一郎; 佐久嶋 研; 浜 結香; 内海 潤; 高橋 育子; 佐藤 和則; 松島 理明, 臨床神経学, 52, 12, 1558, 1558, Dec. 2012
(一社)日本神経学会, Japanese - Association between falls and urinary disturbance in Parkinson's disease
K. Sakushima; S. Yamazaki; Y. Hayashino; S. Fukuhara; I. Yabe; H. Sasaki, EUROPEAN JOURNAL OF NEUROLOGY, 19, 324, 324, Sep. 2012
English, Summary international conference - 骨格筋症状を来した同種骨髄移植後慢性移植片対宿主病の2例
白井 慎一; 上床 尚; 西村 洋昭; 佐久嶋 研; 廣谷 真; 加納 崇裕; 矢部 一郎; 佐々木 秀直, 神経治療学, 29, 5, 656, 656, Sep. 2012
日本神経治療学会, Japanese - 日本における脊髄空洞症全国疫学調査の報告
佐久嶋 研; 坪井 聡; 矢部 一郎; 飛騨 一利; 寺江 聡; 上原 里程; 中野 今治; 佐々木 秀直, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 87, 4, 183, 183, 01 Aug. 2012
Japanese - 当院における処方時の相互作用警告機能の実際と検証
南須原 康行; 佐久嶋 研; 遠藤 晃; 梅木 玲緒奈; 沖 洋充; 山田 武宏; 井関 健; 石川 誠; 宝金 清博, 日本予防医学リスクマネージメント学会学術総会プログラム・抄録集, 10回, 100, 100, Mar. 2012
(一社)日本臨床医学リスクマネジメント学会, Japanese - 神経変性疾患に関する調査研究 パーキンソン病における排尿障害と転倒の関連について
佐々木秀直; 佐久嶋研; 山崎新; 林野泰明; 福原俊一; 矢部一郎, 神経変性疾患に関する調査研究 平成23年度 総括・分担研究報告書, 2012 - パーキンソン病における排尿障害と転倒の関連について
佐久嶋研; 山崎新; 林野泰明; 福原俊一; 矢部一郎; 佐々木秀直, 日本神経学会学術大会プログラム・抄録集, 53rd, 2012 - 脊髄空洞症の第二次全国調査
佐久嶋 研; 矢部 一郎; 佐々木 秀直; 坪井 聡; 上原 里程; 中野 今治, 臨床神経学, 51, 12, 1377, 1377, Dec. 2011
(一社)日本神経学会, Japanese - 当院における成人用転倒・転落アセスメントシートの妥当性についての検討
南須原 康行; 佐久嶋 研; 伊藤 陽一; 奥原 芳子; 渋谷 かをり; 石川 誠; 寶金 清博, 医療の質・安全学会誌, 6, Suppl., 176, 176, Oct. 2011
(一社)医療の質・安全学会, Japanese - 可逆性脳梁膨大部病変を伴い18椎体分に及んだ単純ヘルペスウイルス脊髄炎
白井 慎一; 水戸 泰紀; 佐久嶋 研, 臨床神経学, 50, 2, 128, 128, Feb. 2010
(一社)日本神経学会, Japanese - 抗SS-A抗体陽性患者における中枢神経疾患の臨床的特徴の検討
矢口裕章; 新野正明; 佐久嶋研; 津坂和文; 保前英希; 武井麻子; 矢部一郎; 佐々木秀直, 日本神経学会総会プログラム・抄録集, 51st, 2010 - Progressive Foix-Chavaney-Marie syndrome: a clinico-pathological investigation
M. Otsuki; Y. Nakagawa; F. Mori; H. Tobioka; H. Yoshida; Y. Tatezawa; Y. Tanigawa; I. Takahashi; K. Sakushima; I. Yabe; H. Sasaki; K. Wakabayashi, JOURNAL OF NEUROLOGY, 256, S184, S185, Jun. 2009
English, Summary international conference - 3. 慢性移植片対宿主病(GVHD)により頸部・上肢の筋力低下,嚥下障害を来たした1例(第17回日本リハビリテーション医学会北海道地方会)
浦上 祐司; 生駒 一憲; 佐久嶋 研; 佐々木 秀直; 浦山 良平; 猪原 康子; 堤 昌恵, リハビリテーション医学 : 日本リハビリテーション医学会誌, 45, 10, 686, 687, 18 Oct. 2008
社団法人日本リハビリテーション医学会, Japanese - 特異な髄液所見を呈したLupus myelitisと考えられた1例
高橋育子; 佐久嶋研; 加茂実武; 西村洋昭; 辻幸子; 新野正明; 矢部一郎; 佐々木秀直, 臨床神経学, 48, 2, 2008 - 鑑別に苦慮した中枢性炎症性脱髄性疾患の1例
西村洋昭; 加茂実武; 高橋育子; 佐久嶋研; 辻幸子; 新野正明; 矢部一郎; 佐々木秀直, 臨床神経学, 48, 2, 2008 - 過多月経に伴う高度貧血により脳梗塞を繰り返したと考えられる1例
加茂実武; 高橋育子; 西村洋昭; 佐久嶋研; 辻幸子; 新野正明; 矢部一郎; 佐々木秀直; 家子正裕, 臨床神経学, 48, 2, 2008 - うっ血乳頭にて発見された頭痛を伴わない特発性頭蓋内圧亢進症の1例
佐久嶋 研; 中村 雅一; 松島 理明; 大寺 慶; 辻 幸子; 新野 正明; 矢部 一郎; 佐々木 秀直; 齋藤 理幸, 臨床神経学, 47, 6, 373, 373, Jun. 2007
(一社)日本神経学会, Japanese - 生検にて診断しステロイド大量療法にて軽快したRheumatoid meningitisの一例
矢口 裕章; 松島 理明; 佐久嶋 研; 中村 雅一; 辻 幸子; 新野 正明; 矢部 一郎; 佐々木 秀直, 神経免疫学, 15, 1, 127, 127, Apr. 2007
日本神経免疫学会, Japanese
- 神経疾患治療ストラテジー : 既存の治療・新規治療・今後の治療と考え方
祖父江, 元, 神経疾患のレギュラトリーサイエンスの現状と今後(p.309-320)
中山書店, Sep. 2017, 9784521745435, xi, 451p, Japanese, [Contributor]
- Advancing Clinical Evaluation Guidelines to Accelerate ALS Neurotherapeutic Development in Japan
Ken Sakushima; Koji Fujita; Masashi Aoki; Naoki Atsuta; Makoto Urushitani; Masahisa Katsuno; Osamu Kano; Yuko Kobayakawa; Toshio Shimizu; Akihiro Hirakawa; Yuishin Izumi
American Society for Experimental Neurotherapeutics (ASENT) 2026 Annual Meeting, 04 Mar. 2026, Poster presentation
04 Mar. 2026 - 06 Mar. 2026, 46458066 - シンポジウム 8 「神経変性疾患の薬物治療における新時代の到来」筋萎縮性側索硬化症の治療薬開発と今後の展望
佐久嶋 研
第46回日本臨床薬理学会学術総会, 05 Dec. 2025, Invited oral presentation
05 Dec. 2025 - 06 Dec. 2025, [Invited] - シンポジウム1「国際化・創薬セッション」神経治療学会の国際化の取り組み
佐久嶋 研
第43回日本神経治療学会学術集会, 06 Nov. 2025
06 Nov. 2025 - 08 Nov. 2025, [Invited] - セッション 26『神経治療学の発展に向けて 国際的な神経疾患の開発に貢献するために』筋萎縮性側索硬化症の開発促進に向けて神経治療学会との連携も踏まえて
佐久嶋 研
第22回DIA日本年会2025, 21 Oct. 2025
19 Oct. 2025 - 21 Oct. 2025, [Invited] - ホットトピックス03「神経疾患のドラッグロス問題を考える」筋萎縮性側索硬化症におけるドラッグロスの現状、解決に向けて
佐久嶋 研
第66 回⽇本神経学会学術⼤会, 22 May 2025
21 May 2025 - 24 May 2025, [Invited] - レギュラトリーサイエンスの視点からみるイノベーション推進のポイント
佐久嶋 研
産官学イノベーションスクール(日本神経学会主催), 26 Feb. 2025
[Invited] - シンポジウム「日本のALS治験、治療開発のさらなる推進のために」筋萎縮性側索硬化症に関する治験推進のための医療DX・治験DX
佐久嶋 研
第42回日本神経治療学会学術集会, 08 Nov. 2024
07 Nov. 2024 - 09 Nov. 2024, [Invited] - シンポジウム「神経領域における臨床試験/臨床評価ガイドライン作成の取組み」神経領域における国内外の臨床試験/臨床評価ガイドライン
佐久嶋 研
第42回日本神経治療学会学術集会, 07 Nov. 2024
07 Nov. 2024 - 09 Nov. 2024, [Invited] - データ可視化ツールにおけるCDISC標準利活用の試み
佐久嶋 研
第14回レギュラトリーサイエンス学会学術大会, 13 Sep. 2024, Invited oral presentation
13 Sep. 2024 - 14 Sep. 2024, [Invited] - 講義4 臨床研究各論3 プロトコールに関連するICHガイドライン
佐久嶋 研
厚生労働省 臨床研究総合促進事業 臨床研究・治験従事者研修, 31 Aug. 2024, Public discourse - 診療ガイドラインに示された臨床評価スケールの国際障害分類を用いた体系的分析
佐久嶋 研
第65回日本神経学会学術大会, 30 May 2024, Poster presentation
29 May 2024 - 01 Jun. 2024 - Investigator-initiated Clinical Trials for Neurological Diseases in Japan Pipeline and Support Structures
Ken Sakushima; Harumasa Nakamura; Kazuo Fujihara
American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting, 13 Mar. 2024, Poster presentation
12 Mar. 2024 - 14 Mar. 2024 - Evolution and impact of ODD system in Japan
Ken Sakushima
China Orphan Drug Workshop, 11 Dec. 2023, Others
11 Dec. 2023 - 12 Dec. 2023, [Invited] - アカデミアにおけるCDISC標準準拠データのハンドリング
佐久嶋 研
CDISC 2023 Japan Academic Workshop, 17 Nov. 2023 - シンポジウム12「PMDA に飛び込んでみよう:PMDA とのさらなる連携に向けて」 PMDAでの経験とその後 アカデミアにおけるレギュラトリーサイエンスへ
佐久嶋 研
第41回日本神経治療学会学術集会, 04 Nov. 2023
03 Nov. 2023 - 05 Nov. 2023, [Invited] - 講義4 臨床研究各論3 プロトコールに関連する ICHガイドライン
佐久嶋 研
厚生労働省 臨床研究総合促進事業 臨床研究・治験従事者研修, 15 Sep. 2023, Public discourse - PMDAにおける患者参画検討WGの取組み
佐久嶋 研
第9回DIAクリニカルオペレーション・ モニタリング ワークショップ, Jul. 2021, Invited oral presentation
[Invited] - [S-07-5] 神経疾患治療薬開発の現況と展望-承認審査の立場から
第62回日本神経学会学術大会(京都/オンライン), May 2021, Invited oral presentation
神経疾患には、片頭痛のようなCommon Diseaseから視神経脊髄炎スペクトラム障害のような希少疾病まで様々な疾患が含まれる。これらの神経疾患に対する新規治療として、低分子化合物、抗体製剤、核酸医薬等の様々な種類の医薬品開発が進んでいる。日本で承認された医薬品は審査報告書、申請資料概要等により、開発の概要及び審査における論点等を知ることができる。これらの資料は医薬品医療機器総合機構(PMDA)のウェブサイトで公開されており、医薬品を使用する医療関係者だけではなく、医薬品開発に関わる研究者等にとっても有用な情報である。神経疾患に対して近年承認された医薬品に関して、審査報告書で示されている論点を通して、開発計画、試験デザイン、最終的な効能・効果及び臨床的位置づけ等を紹介するとともに、神経疾患治療薬開発の現況と展望について私見を交えて述べたい。, [Invited] - ICH M11(電子的に構造化された臨床試験プロトコル 調和テンプレート)の取組み(セッション座長)
佐久嶋 研
第17回 DIA 日本年会 2020(東京/オンライン), Nov. 2020, Others - PMDA Joint Symposium: 希少神経疾患の治療開発:現状と課題(セッション座長)
佐久嶋 研
第38回日本神経治療学会学術集会, Oct. 2020, Others - ICH M11: Clinical electronic Structured Harmonised Protocol (CeSHarP)
Ken Sakushima
DIA 2020 Global Annual Meeting (USA/Online), Jun. 2020, English, Invited oral presentation
[Invited] - ICH M11: Clinical electronic Structured Harmonised Protocol (CeSHarP)
Ken Sakushima
DIA Regulatory Submissions, Information, and Document Management Forum (USA), Feb. 2020, English, Invited oral presentation
[Invited] - 神経変性疾患に対する医師主導治験とエビデンス構築 神経変性疾患の臨床試験のポイント
佐久嶋 研
第37回日本神経治療学会(横浜), Nov. 2019, Japanese, Invited oral presentation
[Invited] - 神経難病医療における神経内科医と患者/患者団体の連携 米国FDAにおける患者の声を医薬品開発に反映させるための取組み
佐久嶋 研
. 第60回日本神経学会学術大会(大阪), May 2019, Japanese, Invited oral presentation
[Invited] - 医療現場・臨床試験・レギュラトリーサイエンスのクロストーク
佐久嶋 研
日本臨床試験学会第9回学術集会総会(仙台), Feb. 2018, Japanese, Keynote oral presentation
[Invited] - Regulatory Trends: Regenerative Medicine in Japan
Ken Sakushima
American Society for Experimental NeuroTherapeutics 19th Annual Meeting (USA), Mar. 2017, English, Invited oral presentation
[Invited] - Implementation of CDISC Therapeutic Area Standards in Japan
佐久嶋 研
CDISC 2016 Japan Interchange(東京), Jun. 2016, Japanese, Invited oral presentation
[Invited] - An Update on Biosimilar Regulation in Japan
Ken Sakushima
American Society for Experimental NeuroTherapeutics 18th Annual Meeting (USA), Mar. 2016, English, Invited oral presentation
[Invited] - Clinical trial for regenerative medical products
佐久嶋 研
第12回DIA日本年会(東京), Nov. 2015, Japanese
[Invited] - 病態解析から明らかになった難治性・希少疾患の原因と創薬開発:難病・希少疾病とレギュラトリーサイエンス
佐久嶋 研
日本人類遺伝学会 第60回大会(東京), Oct. 2015, Japanese, Invited oral presentation
[Invited] - 神経疾患の医師主導治験の成功に向けて 審査側からの留意点
佐久嶋 研
第56回日本神経学会学術大会(新潟), May 2015, Japanese, Invited oral presentation
[Invited] - NDA Review of Drugs Developed by Multi-Regional Clinical Trials -Experience of NDA Review in Japan-
佐久嶋 研
第9回DIAアジア新薬開発カンファレンス(東京), Apr. 2015, Japanese, Invited oral presentation
[Invited] - 再生医療等製品:臨床試験の計画・実施におけるポイント(ヒト細胞加工製品を中心に)
佐久嶋 研
第14回日本再生医療学会総会(横浜), Mar. 2015, Invited oral presentation
[Invited] - グローバルな視点で学ぶ創薬と治験推進のための課題 神経領域の治験推進に関連する最近のトピック PMDAの視点から
佐久嶋 研
第32回日本神経治療学会総会, Nov. 2014
20 Nov. 2014 - 22 Nov. 2014 - オーファン薬の臨床開発~審査の立場 から早期探索試験の実施も含めて
佐久嶋 研
第11回DIA日本年会(東京), Nov. 2014, Japanese, Invited oral presentation
[Invited]
- 日本臨床試験学会
- 日本神経治療学会
- European Academy of Neurology
- American Academy of Neurology
- レギュラトリーサイエンス学会
- 日本臨床薬理学会
- 日本医療情報学会
- 日本脳卒中学会
- 日本認知症学会
- 日本神経学会
- 日本内科学会
- Study to develop guidelines for clinical evaluation of amyotrophic lateral sclerosis therapeutics
Research on Regulatory Science of Pharmaceuticals and Medical Devices
Apr. 2024 - Mar. 2026
Yuishin Izumi; Koji Fujita; Masashi Aoki; Naoki Atsuta; Makoto Urushitani; Masahisa Katsuno; Osamu Kano; Ken Sakushima; Toshio Shimizu; Akihiro Hirakawa
AMED, 医薬品等の品質、有効性、安全性等の評価、分析法等の開発に資する研究, Tokushima Universiry, Coinvestigator, 24mk0121294h0001 - 脳神経科学の研究成果を医療と社会のニーズに沿って社会実装するための実用化支援プロジェクト
脳神経科学統合プログラム
Dec. 2024
国立研究開発法人日本医療研究開発機構, 国立大学法人北海道大学, Coinvestigator, 24wm0625011h0001
Social Contribution ActivitiesOthers
